Inflammation significantly influences the degeneration of dopaminergic neurons in Parkinson's disease (PD), which is potentially intensified by associated gut dysbiosis.
Transcriptomic data from an in vitro model is used to predict candidate drug targets for Parkinson’s disease, which are further validated using a drug repurposing approach.
Neuroprotective effects of salidroside (Sal) in PC12 cells against oxidative stress induced by 6-hydroxydopamine (6-OHDA). Sal scavenges reactive oxygen species (ROS), enhances antioxidant enzyme activity (SOD, CAT, GPX4), and reduces α-synuclein (α-syn) accumulation.
Novel thiazole sulfonamides revealed capabilities against 6-OHDA-induced neuronal damage via SIRT1 activity. Thus, these neuroprotective thiazole sulfonamides could be promising candidates for the further development of effective PD therapy.
New triterpenic azines from lupeol exhibited neuroprotective effects in vitro, with 4c notably preventing 6-OHDA- and ferroptosis-induced dopaminergic cell death, highlighting its potential for Parkinson's disease.